In this study, we performed a combined analysis of four NSABP trials with more than 12,000 patients treated with anthracycline-based adjuvant chemotherapy, and with at least 10 years of follow-up. While there was no significant difference in disease free survival and overall survival over the entire follow-up period, stratification by years since diagnosis showed that patients with ILC exhibited increased risk for late DFS events, recurrences, and deaths. We are currently expanding our correlative studies using the primary tumor specimens from this unique, large, annotated cohort of patients with ILC and matched NST with long-term follow up.
Important ILC Research: “Long-term outcomes by lobular vs ductal histology in 4 National Surgical Adjuvant Breast and Bowel Project adjuvant breast cancer trials”
